IN2014CN01970A - - Google Patents

Download PDF

Info

Publication number
IN2014CN01970A
IN2014CN01970A IN1970CHN2014A IN2014CN01970A IN 2014CN01970 A IN2014CN01970 A IN 2014CN01970A IN 1970CHN2014 A IN1970CHN2014 A IN 1970CHN2014A IN 2014CN01970 A IN2014CN01970 A IN 2014CN01970A
Authority
IN
India
Prior art keywords
biomarkers
event
years
risk
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Rosalynn Dianne Gill
Stephen Alaric Williams
Alex A E Stewart
Robert Mehler
Trudi Foreman
Britta Singer
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of IN2014CN01970A publication Critical patent/IN2014CN01970A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
IN1970CHN2014 2011-09-30 2012-09-28 IN2014CN01970A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541828P 2011-09-30 2011-09-30
PCT/US2012/058060 WO2013049674A1 (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Publications (1)

Publication Number Publication Date
IN2014CN01970A true IN2014CN01970A (zh) 2015-05-29

Family

ID=47993164

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1970CHN2014 IN2014CN01970A (zh) 2011-09-30 2012-09-28

Country Status (17)

Country Link
US (3) US20130085079A1 (zh)
EP (1) EP2761289B1 (zh)
JP (3) JP6652781B2 (zh)
KR (2) KR102111624B1 (zh)
CN (4) CN107422126B (zh)
AU (1) AU2013202112B9 (zh)
BR (2) BR112014007214B1 (zh)
CA (2) CA2847903C (zh)
ES (1) ES2777002T3 (zh)
HK (1) HK1247666A1 (zh)
IL (1) IL231387A (zh)
IN (1) IN2014CN01970A (zh)
MX (2) MX2014003153A (zh)
RU (1) RU2651708C2 (zh)
SG (3) SG10201906900QA (zh)
WO (1) WO2013049674A1 (zh)
ZA (1) ZA201401778B (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
JP6055966B2 (ja) * 2010-06-07 2017-01-11 マイクロ‐シグネチャー リミテッド 検出方法
SG10201508656VA (en) 2010-07-09 2015-11-27 Somalogic Inc Lung cancer biomarkers and uses thereof
AU2011289284B2 (en) 2010-08-13 2015-04-09 Somalogic Operating Co., Inc. Pancreatic cancer biomarkers and uses thereof
AU2012225273B2 (en) 2011-03-10 2016-10-13 Somalogic, Inc. Aptamers for Clostridium difficile diagnostics
RU2651708C2 (ru) * 2011-09-30 2018-04-23 Сомалоджик, Инк. Прогнозирование риска сердечно-сосудистого события и его применение
JP6198047B2 (ja) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 冠動脈疾患の検査キット
SG11201602063UA (en) 2013-09-24 2016-04-28 Somalogic Inc Multiaptamer target detection
US20170138961A1 (en) * 2014-03-21 2017-05-18 Sanofi-Aventis Deutschland Gmbh New markers for the assessment of the risk for development of a cardiovascular disorder
CN107076756B (zh) * 2014-06-05 2019-08-16 赛诺菲-安万特德国有限公司 用于评估增加的死亡率风险的新标记物
US10670611B2 (en) * 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
CN108291330A (zh) * 2015-07-10 2018-07-17 西弗吉尼亚大学 卒中和卒中严重性的标志物
RU2602451C1 (ru) * 2015-08-28 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Способ диагностики генетической предрасположенности к развитию ишемического инсульта у больных с фибрилляцией предсердий
US20210215711A1 (en) * 2016-02-08 2021-07-15 Somalogic, Inc. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
EP3426826A4 (en) * 2016-03-09 2019-09-04 Molecular Stethoscope, Inc. METHODS AND SYSTEMS FOR DETECTION OF TISSUE STATES
CA3016107A1 (en) * 2016-04-06 2017-10-12 Nestec S.A. Biomarkers for predicting degree of weight loss
WO2017179699A1 (ja) 2016-04-15 2017-10-19 オムロン株式会社 生体情報分析装置、システム、及び、プログラム
CN105907857A (zh) * 2016-04-29 2016-08-31 天津脉络生物科技有限公司 一种用于动脉血栓的分子标记物和试剂及其应用
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
EP3279665B1 (en) * 2016-08-04 2020-07-08 Roche Diagniostics GmbH Circulating esm-1 (endocan) in the assessment of atrial fibrillation
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
CN111480081A (zh) * 2017-12-13 2020-07-31 豪夫迈·罗氏有限公司 用于预测脑卒中的循环血管生成素-2(Ang-2)和胰岛素样生长因子结合蛋白7(IGFBP7)
RU2685859C1 (ru) * 2018-07-04 2019-04-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития ишемического инсульта
CN109192250B (zh) * 2018-08-01 2021-12-07 华东理工大学 一种多相催化中克服表面物种快速迁移的加速模拟方法
WO2020037244A1 (en) * 2018-08-17 2020-02-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Use of machine learning models for prediction of clinical outcomes
EP3841381A1 (en) * 2018-08-22 2021-06-30 Roche Diagnostics GmbH Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation
CN113287019A (zh) * 2018-10-31 2021-08-20 卡洛斯三世国家心血管研究中心 亚临床动脉粥样硬化的生物标志物
KR102125053B1 (ko) * 2018-12-14 2020-06-19 가톨릭대학교 산학협력단 심혈관계 질환의 검출용 조성물 및 이를 포함하는 키트
GB2612911B (en) 2019-02-14 2023-11-22 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
US11030743B2 (en) * 2019-05-16 2021-06-08 Tencent America LLC System and method for coronary calcium deposits detection and labeling
US10902955B1 (en) 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
WO2022086913A2 (en) * 2020-10-20 2022-04-28 Somalogic Operating Co., Inc. Cardiovascular event risk prediction
RU2750716C1 (ru) * 2020-11-23 2021-07-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных низкого или умеренного сердечно-сосудистого риска путем оценки их психологического статуса
WO2022165393A1 (en) * 2021-02-01 2022-08-04 Medtronic, Inc. A method to identify lvad patients with elevated levels of blood activation using coupon tests
RU2757752C1 (ru) * 2021-04-26 2021-10-21 Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) Способ определения индивидуального профиля факторов суммарного сердечно-сосудистого риска у пациента трудоспособного возраста
WO2023023748A1 (en) * 2021-08-26 2023-03-02 3P Healthcare Pty Ltd System and method for cardiovascular health assessment and risk management
EP4230233A1 (en) * 2022-02-22 2023-08-23 mimiX Biotherapeutics Sàrl Method for producing tissue constructs
WO2023201054A1 (en) * 2022-04-15 2023-10-19 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
WO2001066690A2 (en) * 2000-03-06 2001-09-13 Smithkline Beecham Corporation Novel compounds
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
PT3072978T (pt) * 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
AU2004256425A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
EP1825265A4 (en) * 2004-12-10 2008-08-27 Univ Maryland AMYLOID SERUM PROTEIN USED AGAINST INFLAMMATION AND OBESITY
CN2783324Y (zh) * 2005-04-28 2006-05-24 穆海东 心血管疾病诊断和预测多指标蛋白芯片检测试剂盒
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
AU2007210643B2 (en) * 2006-01-31 2013-09-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for determination of condition of disseminated intravascular coagulation syndrome
EP2030025A2 (en) * 2006-06-07 2009-03-04 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
RU2376372C2 (ru) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
HUE025283T2 (en) * 2007-08-02 2016-03-29 Gilead Biologics Inc LOX and LOX2 inhibitors and their use
GB0717637D0 (en) * 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
WO2009091581A2 (en) * 2008-01-18 2009-07-23 Vatrix Medical, Inc. Diagnostic biomarkers for vascular aneurysm
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
CA2733556A1 (en) * 2008-08-11 2010-02-18 The Board Of Regents Of The University Of Texas System A micro-rna that promotes vascular integrity and uses thereof
EP2353011B1 (en) * 2008-10-07 2020-03-04 B.R.A.H.M.S GmbH Biomarker for the prediction of first adverse events
AU2010259022B2 (en) * 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
EP2264183B1 (en) * 2009-06-09 2016-12-07 Gendiag.exe, S.L. Risk markers for cardiovascular disease
SG176692A1 (en) * 2009-06-15 2012-01-30 Cardiodx Inc Determination of coronary artery disease risk.
EP2494364A1 (en) 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
WO2011072177A2 (en) * 2009-12-09 2011-06-16 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
AU2011223527B2 (en) * 2010-03-03 2014-11-13 Somalogic Operating Co., Inc. Aptamers to 4-1BB and their use in treating diseases and disorders
RU2651708C2 (ru) * 2011-09-30 2018-04-23 Сомалоджик, Инк. Прогнозирование риска сердечно-сосудистого события и его применение
JP6124986B2 (ja) * 2012-03-19 2017-05-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 拡張期心不全を処置するための増殖分化因子（ｇｄｆ）

Also Published As

Publication number Publication date
US20200166523A1 (en) 2020-05-28
AU2013202112B2 (en) 2015-09-24
KR20200055804A (ko) 2020-05-21
CA2847903A1 (en) 2013-04-04
CN107422126B (zh) 2020-03-27
JP2014528576A (ja) 2014-10-27
CN114518458A (zh) 2022-05-20
EP2761289B1 (en) 2020-02-12
CN103959060A (zh) 2014-07-30
ZA201401778B (en) 2018-08-25
IL231387A0 (en) 2014-04-30
IL231387A (en) 2017-12-31
BR112014007214B1 (pt) 2022-08-16
MX2014003153A (es) 2014-04-30
BR122019023720B1 (pt) 2023-01-24
US20150168423A1 (en) 2015-06-18
KR20140084106A (ko) 2014-07-04
CN107102151A (zh) 2017-08-29
MX2020004617A (es) 2020-08-06
US20130085079A1 (en) 2013-04-04
JP2018159713A (ja) 2018-10-11
AU2013202112B9 (en) 2015-10-22
KR102248900B1 (ko) 2021-05-07
BR112014007214A2 (pt) 2017-04-04
CN107422126A (zh) 2017-12-01
SG11201400904SA (en) 2014-04-28
CA3074279C (en) 2021-10-19
NZ622118A (en) 2016-01-29
JP6917432B2 (ja) 2021-08-11
SG10201906900QA (en) 2019-09-27
SG10201607331WA (en) 2016-11-29
JP6546318B2 (ja) 2019-07-17
HK1247666A1 (zh) 2018-09-28
BR122019023720A8 (pt) 2022-07-26
CA3074279A1 (en) 2013-04-04
CN103959060B (zh) 2017-05-17
BR122019023720A2 (zh) 2017-04-04
EP2761289A4 (en) 2015-08-12
RU2651708C2 (ru) 2018-04-23
EP2761289A1 (en) 2014-08-06
CA2847903C (en) 2020-10-27
AU2013202112A1 (en) 2013-05-02
RU2014110508A (ru) 2015-11-10
WO2013049674A1 (en) 2013-04-04
ES2777002T3 (es) 2020-08-03
KR102111624B1 (ko) 2020-05-18
JP6652781B2 (ja) 2020-02-26
BR112014007214A8 (pt) 2022-07-26
JP2020024216A (ja) 2020-02-13

Similar Documents

Publication Publication Date Title
IN2014CN01970A (zh)
MX350533B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
IN2014CN01787A (zh)
EA030186B9 (ru) Способ проведения количественных анализов
MY170164A (en) Aptamer-based multiplexed assays
WO2013052505A3 (en) Methods and devices for assessing risk to a putative offspring of developing a condition
WO2014186761A3 (en) Methods for determining responsiveness to an anti-cd47 agent
WO2013075055A3 (en) Kits and methods for assessing appendicitis
EP3029153A3 (en) Mesothelioma biomarkers and uses thereof
WO2012177945A3 (en) Diagnostic methods for eosinophilic esophagitis
WO2012019193A3 (en) Assay systems for genetic analysis
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
WO2013188686A3 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
GB201207297D0 (en) Analytical methods and arrays for use in the same
MX2015001961A (es) Metodos y sistemas para ensayos.
WO2011137388A3 (en) Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample
WO2013112836A3 (en) Diagnostic and prognostic biomarkers for cancer
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
IN2015DN01501A (zh)
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
MX2015004419A (es) Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables.
GB201206323D0 (en) Methods and arrays for use in the same
EP3557259A3 (en) Methods and arrays for use in the same
WO2012139051A3 (en) Autoantibody biomarkers for iga nephropathy